Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease
Open Access
- 27 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 27 (8) , 1237-1247
Abstract
Fecal lactoferrin (FL) levels may mirror drug-induced changes in inflammation in ulcerative colitis and Crohn disease in a timely way and could be used to assess loss of response (LOR) to biologics. This study is a retrospective outcome review in 61 patients on adalimumab, infliximab, or vedolizumab managed in our center and followed for 6 to 24 months. Patients were 1) in clinical remission or 2) were experiencing possible LOR. For group 1, in 71% of 31 patients, FL slowly increased during the therapeutic interval (R2 = 0.769; P < 0.001), thus reflecting increasing inflammation as drug concentrations decreased. In the remaining patients, FL was undetectable throughout the therapeutic interval because of a stronger suppression of inflammation. For group 2, in 30 patients negative for infections, FL levels measured 1 to 3 days after infusion/injection compared to preadministration values either increased (nonresponders)—in these patients the medication was switched to another class; partially decreased (partial responders)—the therapeutic interval was shortened; or were normal throughout (responders)—causes for symptoms unrelated to disease activity were found for all. After FL-based management, 3-month standardized clinical scores were normalized in both partial responders (0.58 ± 0.21 vs 0.13 ± 0.09; P < 0.001) and nonresponders (0.81 ± 0.17 vs 0.12 ± 0.08; P < 0.001), and FL levels dropped by up to 99%. Levels of FL reflect drug-induced changes in mucosal inflammation in a timely way, thus enabling rapid assessment of therapeutic response in patients with ulcerative colitis and with Crohn disease. In patients with suspected LOR, FL levels before and after infusion/injection accurately separated responders, partial responders, and nonresponders. The strategy proposed here is simple, accurate, and easily applicable to clinical practice.Keywords
This publication has 36 references indexed in Scilit:
- Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease PatientsGastroenterology, 2015
- Role of Biomarkers in the Study and Management of Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Measuring disease activity in Crohn's disease: what is currently available to the clinicianClinical and Experimental Gastroenterology, 2014
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximabGut, 2013
- A general and simple method for obtaining R2 from generalized linear mixed‐effects modelsMethods in Ecology and Evolution, 2012
- Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2012
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapyAlimentary Pharmacology & Therapeutics, 2011
- Diagnosis and assessment of Crohn’s disease: the present and the futureExpert Review of Gastroenterology & Hepatology, 2010
- Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's DiseaseClinical Gastroenterology and Hepatology, 2010
- Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexesBMC Research Notes, 2009